Möchten Sie immer auf dem neuesten Stand bleiben?

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...

Dublin, March 01, 2023 (GLOBE NEWSWIRE) -- The "Global Gene Cloning Services Market by Service Type, Gene Type, Application, End-user, and Region: Competition Forecast and Opportunities to 2027"...

Dublin, March 01, 2023 (GLOBE NEWSWIRE) -- The "Europe Advanced Therapy Medicinal Products CDMO Market Size, Share & Industry Trends Analysis Report By Indication, By Product, By Phase, By...

Dublin, Feb. 28, 2023 (GLOBE NEWSWIRE) -- The "North America GMP Cell Therapy Consumables Market Forecast to 2028 - COVID-19 Impact and Regional Analysis" report has been added to ...

Dublin, Feb. 28, 2023 (GLOBE NEWSWIRE) -- The "Plasmid DNA Manufacturing Market, By Product Type, By Grade, By Application, By Manufacturing Type, By Development Phase, By Region - Size, Share,...

REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...

~ Achieved U.S. and European Commission marketing approvals of first and only gene therapyfor adults with hemophilia B ~ ~ Advancing development of AMT-130 for patients with Huntington’s disease –...

Dublin, Feb. 24, 2023 (GLOBE NEWSWIRE) -- The "Global Cell & Gene Therapy Business and Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial...

~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for...

~ Historic approval represents the first gene therapy in Europe to treat hemophilia B and provides a new treatment option for patients that reduces the rate of annual bleeds, reduces or eliminates the...